Updated Jul 16, 2026
Sheridan John F has filed 2 SEC Form 4 filings across 1 company in the last 90 days — buying. Lifetime open-market purchases: $102K.

John F. Sheridan is the President and CEO of Tandem Diabetes Care, Inc., a company specializing in insulin pump technology for diabetes management. He has played a significant role in the company's growth and product development since its inception.
| Role | PRESIDENT & CEO, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-19 | TNDM | TANDEM DIABETES CARE INC | A — Grant or award | 1.3K | $10.90 | $15K |
| 2026-05-19 | TNDM | TANDEM DIABETES CARE INC | F — Tax withholding / forfeiture | 18.9K | $12.82 | $243K |
| 2026-05-19 | TNDM | TANDEM DIABETES CARE INC | M — Option exercise | 39.7K | $0.00 | |
| 2026-05-19 | TNDM | TANDEM DIABETES CARE INC | F — Tax withholding / forfeiture | 3.0K | $12.82 | $39K |
| 2026-05-19 | TNDM | TANDEM DIABETES CARE INC | M — Option exercise | 6.0K | $0.00 | |
| 2026-05-19 | TNDM | TANDEM DIABETES CARE INC | F — Tax withholding / forfeiture | 2.8K | $12.82 | $36K |
| 2026-05-19 | TNDM | TANDEM DIABETES CARE INC | M — Option exercise | 5.5K | $0.00 | |
| 2026-02-19 | TNDM | TANDEM DIABETES CARE INC | F — Tax withholding / forfeiture | 2.4K | $18.95 | $45K |
| 2026-02-19 | TNDM | TANDEM DIABETES CARE INC | M — Option exercise | 6.0K | $0.00 | |
| 2026-02-19 | TNDM | TANDEM DIABETES CARE INC | F — Tax withholding / forfeiture | 2.0K | $18.95 | $37K |
| 2026-02-19 | TNDM | TANDEM DIABETES CARE INC | M — Option exercise | 5.5K | $0.00 | |
| 2025-08-15 | TNDM | TANDEM DIABETES CARE INC | F — Tax withholding / forfeiture | 3.0K | $10.82 | $33K |
| 2025-08-15 | TNDM | TANDEM DIABETES CARE INC | M — Option exercise | 6.0K | $0.00 | |
| 2025-08-15 | TNDM | TANDEM DIABETES CARE INC | F — Tax withholding / forfeiture | 2.8K | $10.82 | $30K |
| 2025-08-15 | TNDM | TANDEM DIABETES CARE INC | M — Option exercise | 5.5K | $0.00 | |
| 2025-08-11 | TNDM | TANDEM DIABETES CARE INC | P — Open-market purchase | 10.0K | $10.23 | $102K |
| 2024-11-19 | TNDM | TANDEM DIABETES CARE INC | A — Grant or award | 381 | $15.64 | $6K |
| 2024-11-19 | TNDM | TANDEM DIABETES CARE INC | F — Tax withholding / forfeiture | 2.8K | $27.34 | $76K |
| 2024-11-19 | TNDM | TANDEM DIABETES CARE INC | M — Option exercise | 5.5K | $0.00 | |
| 2024-11-19 | TNDM | TANDEM DIABETES CARE INC | F — Tax withholding / forfeiture | 1.1K | $27.34 | $31K |
John F. Sheridan is the President and CEO of Tandem Diabetes Care, Inc., a company specializing in insulin pump technology for diabetes management. He has played a significant role in the company's growth and product development since its inception.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($102K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Sheridan John F profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.